This trial is testing whether the drug durvalumab, in combination with standard chemotherapy, is safe and effective for treating stage IV non-small-cell lung cancer (NSCLC) in patients with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection.
2 Primary · 3 Secondary · Reporting Duration: 36 months
18 Total Participants · 1 Treatment Group
Primary Treatment: Durvalumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: